<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13D-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13D-2(A)
(AMENDMENT NO. 8)
VWR SCIENTIFIC PRODUCTS CORPORATION
------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $1.00 PER SHARE
------------------------------------------------------------------
(Title of Class of Securities)
918435 10 8
------------------------------------------------------------------
(CUSIP Number)
KLAUS H. JANDER, ESQ.
RICHARD T. MCDERMOTT, ESQ.
ROGERS & WELLS LLP
200 PARK AVENUE
NEW YORK, NY 10166
(212) 878-8000
------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
JULY 20, 1999
------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box |_|
Note. Schedules filed in paper format should include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for the other
parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 4 Pages)
<PAGE> 2
<TABLE>
<CAPTION>
- --------------------------------- -------------------------------
CUSIP NO. 918435 10 8 13D PAGE 2 OF 4 PAGES
- --------------------------------- -------------------------------
<S> <C>
============ =======================================================================================================
1. NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
EM Laboratories, Incorporated
============ =======================================================================================================
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)|_|
(b)|_|
============ =======================================================================================================
3. SEC USE ONLY
============ =======================================================================================================
4. SOURCES OF FUNDS
AF
============ =======================================================================================================
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|_|
============ =======================================================================================================
6. CITIZENSHIP OR PLACE OF ORGANIZATION
New York
- ------------------------- ------- ==================================================================================
7. SOLE VOTING POWER
NUMBER OF
UNITS 27,751,488
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
------- ==================================================================================
8. SHARED VOTING POWER
0
------- ==================================================================================
9. SOLE DISPOSITIVE POWER
27,751,488
------- ==================================================================================
10. SHARED DISPOSITIVE POWER
0
============ =======================================================================================================
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
27,751,488
============ =======================================================================================================
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
============ =======================================================================================================
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
95.8%
============ =======================================================================================================
14. TYPE OF REPORTING PERSON
CO
============ =======================================================================================================
</TABLE>
2
<PAGE> 3
SCHEDULE 13D
FILED PURSUANT TO RULE 13d-1
OF THE GENERAL RULES AND REGULATIONS UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
This Amendment No. 8, which relates to shares of the common stock, par
value $1.00 per share (the "Common Stock") of VWR Scientific Products
Corporation (the "Issuer") and is being filed by EM Laboratories, Inc. ("EML"),
supplements and amends the statement on Schedule 13D originally filed with the
Commission, as amended.
ITEM 4. PURPOSE OF THE TRANSACTION.
Item 4 is amended as follows:
As previously reported, the tender offer by EML's wholly owned subsidiary, EM
Subsidiary, Inc., for all outstanding shares of the Issuer expired, as
scheduled, at 12:00 midnight on Tuesday, July 13, 1999, New York City time. A
total of 13,302,084 shares were tendered and accepted for payment. As a result
of the tender offer, EM Laboratories and its affiliates own 27,751,488 shares of
the Issuer, representing approximately 95.8% of the issued and outstanding
shares.
On Tuesday, July 20, 1999, EM Subsidiary, Inc. began making cash payments of
$37.00 per share, the consideration due to holders of shares that were tendered
and accepted for payment.
3
<PAGE> 4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: July 20, 1999
EM LABORATORIES, INCORPORATED
By: /s/ Stephen J. Kunst
Name: Stephen J. Kunst
Title: Vice-President and Secretary
4
